Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
Authors:
- 27 February 2009
- journal article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 15 (4) , 505-508
Abstract
Background Therapy-related acute leukaemia (TRAL) is a concern for neurologists and patients when considering treatment with Mitoxantrone for multiple sclerosis (MS). The timing of this complication, risk, mortality and relationship to exposure remain uncertain. Methods We searched literature for publications relating to Mitoxantrone in MS, reviewed publication references and handsearched abstract lists to identify case-series reporting follow-up and complications of treatment with Mitoxantrone. We combined this with our local database of 250 cases treated since 1997. We also identified all reported individual cases of TRAL and extracted data reporting exposure (dose or mg/m2), timing and outcome of TRAL. Results Case-series including 5472 patients were identified; mean dose of Mitoxantrone was 74.2 mg/m2 (range:12–120 mg/m2). TRAL was diagnosed in 0.30% (1 in 333). In 34 TRAL cases, sufficient data was available to inform analysis of exposure. Onset was a median of 18.5 months following Mitoxantrone treatment (range:4–60). Acute Myelocytic Leukaemia and Acute Promyelocytic Leukaemia represented 46.4% each of the leukaemia subtypes. Six of 25 TRAL patients, where outcome was reported, died (24%). Over 80% of cases occurred in patients exposed to >60 mg/m2, with a relative risk of 1.44 (CI95%:1.18–1.70) when comparing total dose >60 mg/m2 against 2 strongly suggesting a relationship between risk of TRAL and total dose.Keywords
This publication has 14 references indexed in Scilit:
- Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patientsJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosisMultiple Sclerosis Journal, 2007
- Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosisJournal of Neurology, 2006
- Fertility in patients with multiple sclerosis: current knowledge and future perspectivesNeurological Sciences, 2006
- Management of worsening multiple sclerosis with mitoxantrone: A reviewClinical Therapeutics, 2006
- DNA Topoisomerase II in Therapy-Related Acute Promyelocytic LeukemiaNew England Journal of Medicine, 2005
- Rationale for the use of mitoxantrone in multiple sclerosisJournal of the Neurological Sciences, 2004
- Letter to the EditorMultiple Sclerosis Journal, 2003
- Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MSNeurology, 2002
- Multiple sclerosisThe Lancet, 2002